Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
US Department of Justice
Medtronic
Accenture
AstraZeneca
Fuji
Novartis
Dow
Chinese Patent Office
Deloitte

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021821

« Back to Dashboard

NDA 021821 describes TYGACIL, which is a drug marketed by Pf Prism Cv and is included in one NDA. It is available from one supplier. There are five patents protecting this drug and one Paragraph IV challenge. Additional details are available on the TYGACIL profile page.

The generic ingredient in TYGACIL is tigecycline. There are ten drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the tigecycline profile page.
Summary for 021821
Tradename:TYGACIL
Applicant:Pf Prism Cv
Ingredient:tigecycline
Patents:5
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details
Pharmacology for NDA: 021821
Ingredient-typeTetracyclines
Suppliers and Packaging for NDA: 021821
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TYGACIL tigecycline POWDER;IV (INFUSION) 021821 NDA Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. 0008-4990 N 0008-4990-20
TYGACIL tigecycline POWDER;IV (INFUSION) 021821 NDA Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. 0008-4990 N 0008-4990-02

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;IV (INFUSION)Strength50MG/VIAL
Approval Date:Jun 15, 2005TE:APRLD:Yes
Patent:➤ Sign UpPatent Expiration:Feb 5, 2029Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Sign UpPatent Expiration:Oct 8, 2030Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Sign UpPatent Expiration:Oct 24, 2028Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 021821

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pf Prism Cv TYGACIL tigecycline POWDER;IV (INFUSION) 021821-001 Jun 15, 2005 ➤ Sign Up ➤ Sign Up
Pf Prism Cv TYGACIL tigecycline POWDER;IV (INFUSION) 021821-001 Jun 15, 2005 ➤ Sign Up ➤ Sign Up
Pf Prism Cv TYGACIL tigecycline POWDER;IV (INFUSION) 021821-001 Jun 15, 2005 ➤ Sign Up ➤ Sign Up
Pf Prism Cv TYGACIL tigecycline POWDER;IV (INFUSION) 021821-001 Jun 15, 2005 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Cerilliant
US Department of Justice
Covington
Julphar
Harvard Business School
Chubb
Accenture
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot